New Data Demonstrates 5-FU Personalized Chemotherapy Management Assay Provides Similar Performance to More Complicated LC-MS/MS
News Jun 26, 2008
A new blood test may make it easier for oncologists to accurately measure and personalize 5-fluorouracil (5-FU) dosing for patients undergoing continuous infusion chemotherapy regimens.
Data from a multicenter trial showed that a nanoparticle-based immunoassay from Saladax Biomedical, called 5-FU Personalized Chemotherapy Management (PCM®), performed as well as high performance liquid chromatography (HPLC) or LC-MS/MS, but was easier to use, more rapid and more amenable to widespread clinical use.
The data was presented at the 2008 Hematology/Oncology Pharmacy Association and the International Society of Oncology Pharmacy Practitioners' (HOPA/ISOPP) annual meeting in Anaheim, Calif.
5-FU is a cornerstone treatment regimen for colorectal cancer; the third leading cause of cancer deaths in the United States.
"This evidence-based tool for monitoring the actual drug concentrations of 5-FU in the blood will enable simplified, personalized dose management with the goal of minimizing toxicity and maximizing the therapeutic benefit of 5-FU treatment," said Salvatore Salamone, Ph.D., CEO of Saladax Biomedical.
"This is important because a significant amount of scientific evidence over the last decade demonstrates that the effectiveness of the 5-FU regimen is burdened by potentially severe and life-threatening side effects."
To date, analysis of 5-FU blood plasma levels could only be performed by complex, labor-intensive, expensive, and physical analytical methods such as HPLC that have insufficient capacity to be used in high volume clinical settings.
The 5-FU PCM assay could provide the same HPLC or LC-MS/MS-like performance, while offering advantages of automation, small sample size, and improved turn-around time for oncologists.
The multicenter study evaluated 5-FU blood plasma levels at three sites, according to the Clinical and Laboratory Standards Institute (CLSI) protocol. 5-FU blood plasma levels were evaluated using the 5-FU PCM assay and cross- analyzed using LC-MS/MS cross-reactivity, precision, and stability to ensure accuracy. Researchers found that the PCM assay was precise and analytical results correlated well with those obtained from the validated HPLC method.
A recent study demonstrated that monitoring patients' 5-FU blood plasma levels and adjusting chemotherapy doses to achieve optimal levels of 5-FU can improve response rates and minimize toxicity when compared to standard-of-care dosing based on height and weight (known as body surface area or BSA).
The May issue of the Journal of Clinical Oncology (JCO) featured results of a Phase III randomized study of colorectal cancer patients who were dosed with 5-FU based on the current standard, BSA compared with patients who had doses personalized according to 5-FU blood plasma levels.
The study concluded that only 25 percent of patients were in target range, while 17 percent were found to be over-dosed and 58 percent of patients were found to be under-dosed.
Additionally, this study demonstrated that after 5-FU doses was adjusted to achieve appropriate plasma levels, patients experienced improved response rates and nearly doubled overall survival, in addition to significantly lower toxicity.
The Friedrich Schiller University Jena Partners with ACD/Labs to Advance its Analytical Data Management StrategyNews
Implementation of ACD/Spectrus as an analytical data management system helps researchers and students streamline NMR and MS data processing, interpretation, collaboration, and training.READ MORE
1 in 3 U.S. Adults May Be Using Medications That Have Potential to Cause DepressionNews
A new study from University of Illinois at Chicago researchers suggests that more than one-third of U.S. adults may be using prescription medications that have the potential to cause depression or increase the risk of suicide.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE